Missed November statement from Stockopedia. Assumed you were on holiday! Then as days stretched to weeks, thought you might be on sabbatical! Great to 'find' you again and enjoyed the podcast, as usual. Best of luck in your new venture and I echo Harry's comment about the wisdom of building a large community.
For what it’s worth I’ve also seen an uptick across the board of all my small cap holdings, pretty well all of them on no news. All well known by yourself and your readers.
Very welcome after the last few months but Im still a bit wary . It’s only after a couple of weeks and we’ve seen these short term changes reverse pretty rapidly. However, I will be making some modest top ups.
By the way, I think your strategy of making subscriptions very cheap ( which they are) in order to create a large community of discussions is a brilliant one.
COG.L Just a bit more light on Cog. Paul it was a good time to loose interest in Cog a couple of years ago when they launched into a couple of possibly ill timed takeovers and certainly stretched the finances enough to need a hasty cash injection from a German healthcare finance specialist on not the best terms, followed by a discounted placing @40p in the autumn. 4 weeks after that the CEO, Mathew Stork, left or was booted out. That had a further impact on the share price to 27p as it was all a bit secretive. He has no financial interest left in the company, it seems pretty clear he was sacked. Currently the company is run by two directors who are each being considered for permanent CEO position along with other interviews for the post.
The brightest part recently has been their 22% stake in their spinoff Monument therapeutics who were recently awarded £1 million by Foster Foundation for the development of two schizophrenic drugs to begin clinical trials early next year ‘at a post investment valuation of £8.35 million.’
Cog’s main rival is an Australian company called Cosgate. Nice and confusing. They are much further established globally and financially but many consider Cog a far superior company in diagnostics and therapies. Both in the same area of Alzheimer's and Parkinson studies.
Despite the undoubted financial hash the management have made of Cog they have attracted some big new investors . I listened to a sparkling interview with DrJenny Bartlett earlier in the year, who heads up Monument and feels the whole neurology science area is going to make some very significant progress soon. Today was another surprising market reaction to a severe profit warning, but if as forecast they start rapid cash generation next year and they can convert even half the pipeline to orders this could be a good entry point. I took part in the placing and bought a few more in the subsequent drop.
Hope you feel refreshed. Big fan of the afternoon nap especially with this weather! Bad enough on the east coast.
Missed November statement from Stockopedia. Assumed you were on holiday! Then as days stretched to weeks, thought you might be on sabbatical! Great to 'find' you again and enjoyed the podcast, as usual. Best of luck in your new venture and I echo Harry's comment about the wisdom of building a large community.
Thanks for this Paul
For what it’s worth I’ve also seen an uptick across the board of all my small cap holdings, pretty well all of them on no news. All well known by yourself and your readers.
Very welcome after the last few months but Im still a bit wary . It’s only after a couple of weeks and we’ve seen these short term changes reverse pretty rapidly. However, I will be making some modest top ups.
By the way, I think your strategy of making subscriptions very cheap ( which they are) in order to create a large community of discussions is a brilliant one.
COG.L Just a bit more light on Cog. Paul it was a good time to loose interest in Cog a couple of years ago when they launched into a couple of possibly ill timed takeovers and certainly stretched the finances enough to need a hasty cash injection from a German healthcare finance specialist on not the best terms, followed by a discounted placing @40p in the autumn. 4 weeks after that the CEO, Mathew Stork, left or was booted out. That had a further impact on the share price to 27p as it was all a bit secretive. He has no financial interest left in the company, it seems pretty clear he was sacked. Currently the company is run by two directors who are each being considered for permanent CEO position along with other interviews for the post.
The brightest part recently has been their 22% stake in their spinoff Monument therapeutics who were recently awarded £1 million by Foster Foundation for the development of two schizophrenic drugs to begin clinical trials early next year ‘at a post investment valuation of £8.35 million.’
Cog’s main rival is an Australian company called Cosgate. Nice and confusing. They are much further established globally and financially but many consider Cog a far superior company in diagnostics and therapies. Both in the same area of Alzheimer's and Parkinson studies.
Despite the undoubted financial hash the management have made of Cog they have attracted some big new investors . I listened to a sparkling interview with DrJenny Bartlett earlier in the year, who heads up Monument and feels the whole neurology science area is going to make some very significant progress soon. Today was another surprising market reaction to a severe profit warning, but if as forecast they start rapid cash generation next year and they can convert even half the pipeline to orders this could be a good entry point. I took part in the placing and bought a few more in the subsequent drop.
Hope you feel refreshed. Big fan of the afternoon nap especially with this weather! Bad enough on the east coast.